Clinical trials: Chronic Pulmonary Obstruction
Pulmonary Disease, Chronic Obstructive
Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy
A multicenter study to evaluate lung function and symptoms in subjects with COPD who have been on regular use of only one long-acting bronchodilator.
- Trial name
- LABD (NCT00791518)
- Testing
- No intervention
- Where
- 57 sites in United States
- Volunteers
- 1,084 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease, Lung Cancer
COPD Care Pathway Among Patients With Cancer
This study gathers information for the development of a COPD care pathway for patients with cancer that reduces the treatment burden of patients, implements critical components of COPD care, and overcomes common barriers to COPD…
- Conditions
- Chronic Obstructive Pulmonary Disease, Lung Cancer, Head and Neck Cancer
- Trial name
- NCT05984680
- Testing
- Observational Phase 1, Observational Phase 2, Group I, Observational Phase 2, Group II
- Where
- United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
COPD, Coronary Artery Calcification
Quebec Lung Cancer Screening PLUS Trial
Does an educational intervention for untreated COPD and cardiovascular disease which is integrated in an existing lung cancer screening program improve guideline concordant medication adherence at 12 months
- Trial name
- QLC+ (NCT05444062)
- Testing
- Educational material and treatment recommendations for patients, general practitioners and pharmacists
- Where
- Canada
- Volunteers
- 330 people
- Sponsor
- Nicole Ezer, MD, FRCPC, MPH
Chronic Obstructive Pulmonary Disease
Effects of an Air Purifying Device (PureNight) on Sleep Quality in Obstructive Lung Disease
Many individuals with chronic lung disease have night time symptoms that disrupt their sleep. The purpose of this study is to determine the effects of an air purifying device (PureNight, Halo Innovations, Minneapolis, MN) on…
- Trial name
- NCT01772342
- Testing
- HEPA filtration
- Volunteers
- 50 people
- Sponsor
- VA New York Harbor Healthcare System
Heart Failure, Chronic Obstructive Pulmonary Disease
Effects of HIIT in Tolerance to Exercise of Individuals With HF and Coexisting COPD
INTRODUCTION: The complexity of the pathophysiology of heterogeneous diseases such as heart failure and obstructive pulmonary disease causes a different approach to these diseases or with a view as much as a better understanding…
- Trial name
- NCT04350541
- Testing
- High-intensity interval training, Continuous aerobic training
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Universidade Federal de Pernambuco
COPD
Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
The purpose of this research study is to determine the amount of medicine absorbed in the lungs following dosing via eFlow nebulizer and Seebri® Breezhaler® with and without activated charcoal in subjects with moderate to severe…
- Trial name
- GOLDEN7 (NCT02512302)
- Testing
- SUN-101 via eFlow nebulizer, SUN-101 via eFlow nebulizer with activated charcoal, Seebri® Breezhaler®
- Where
- 2 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Sunovion Respiratory Development Inc.
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Safety and Effectiveness of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease
This study is being conducted to see if PRX-08066 can lower pulmonary artery pressures in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease.
- Trial name
- NCT00345774
- Testing
- PRX-08066
- Where
- 19 sites in United States
- Volunteers
- 72 people
- Sponsor
- Epix Pharmaceuticals, Inc.
Asthma, Chronic Obstructive Pulmonary Disease
Reliability of a Top Mount Actuation Indicator With Levalbuterol MDI in Adult and Pediatric Subjects With Asthma or COPD
This is a study to investigate the reliability, ruggedness and safety of the top mounted actuation indicator (TMAI) when used with Levalbuterol HFA MDI.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, COPD
- Trial name
- NCT00583986
- Testing
- Levalbuterol HFA MDI with top mounted actuation indicator
- Where
- 26 sites in United States
- Volunteers
- 150 people
- Sponsor
- Sumitomo Pharma America, Inc.
Chronic Obstructive Pulmonary Disease
Placebo Versus Antibiotics in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
The role of antibiotic therapy in patients with COPD remains controversial. While the outcome of several clinical trials is in favour of antibiotics, the quality of these studies in insufficient.
- Trial name
- NCT00170222
- Testing
- doxycycline
- Where
- Netherlands
- Volunteers
- 258 people
- Sponsor
- Medical Center Alkmaar
Chronic Obstructive Pulmonary Disease
Replication of the POET-COPD Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT05083429
- Testing
- Salmeterol, Tiotropium
- Where
- United States
- Volunteers
- 8,716 people
- Sponsor
- Brigham and Women's Hospital
COPD
TELE-monitoring in Chronic Obstructive Pulmonary Disease
COPD is the fourth cause of death worldwide and it is expected to be the third in 2020. Non-invasive ventilation (NIV) has a positive impact in reducing mortality related to chronic respiratory failure in stable patients with…
- Trial name
- TELECOPD (NCT03129477)
- Testing
- Telemonitoring in noninvasive ventilation
- Where
- Portugal
- Volunteers
- 50 people
- Sponsor
- Conde, Bebiana, M.D.
Chronic Obstructive Pulmonary Disease
Evaluation of the Effectiveness, Safety, and Cost of a Smart Hospital System for Patients With Chronic Obstructive Pulmonary Disease
This study aims to analyze the effectiveness/safety/cost of the Smart Homespital system that provides a service that allows patients with Chronic Obstructive Pulmonary Disease to easily access and use biosignals generated using…
- Trial name
- NCT06601777
- Testing
- Immediate application of the Smart Homespital system, Delayed application of the Smart Homespital system after 3 months
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Yonsei University
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive
Genetic Factors That Influence Chronic Obstructive Pulmonary Disease in Hispanics
The purpose of this study is to examine genetic factors that influence the development of chronic obstructive pulmonary disease (COPD) in Hispanics, a minority group at high risk for the disease.
- Trial name
- NCT00106470
- Where
- Costa Rica
- Volunteers
- 679 people
- Sponsor
- University of Pittsburgh
Chronic Obstructive Pulmonary Disease (COPD)
A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.
This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to severe airflow limitation.
- Trial name
- NCT01727141
- Testing
- QVA149, QAB149, NVA237
- Where
- 143 sites in United States, Canada and 6 more
- Volunteers
- 1,042 people
- Sponsor
- Novartis Pharmaceuticals
COPD
Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to determine the safety and tolerability of single doses of QAB149 up to 3000 µg delivered via a single-dose, dry powder inhaler in patients with mild to moderate COPD.
- Trial name
- NCT00129831
- Testing
- QAB149
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice
Post-marketing surveillance to gather information regarding the tolerance and efficacy of Spiriva® 18 micrograms in patients with COPD under conditions of daily practice.
- Trial name
- NCT02172495
- Testing
- Tiotropium bromide
- Volunteers
- 4,700 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
The Effect of Singing or Playing Melodica in COPD Patients
This study was conducted as a randomized controlled experimental study to determine the effect of singing or playing melodica activity applied to chronic obstructive pulmonary patients on symptoms, self-efficacy level, and…
- Trial name
- COPD (NCT05168241)
- Testing
- song/melodica group, control group
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Karadeniz Technical University
Chronic Obstructive Pulmonary Disease
Consequences of Nocturnal and Daytime Hypoxemia in COPD
We will determine whether oxygen therapy lowers the level of substances in the blood which cause inflammation, which is one of the adverse effects of COPD and whether oxygen improves overall well being and quality of life as well…
- Trial name
- NCT00547456
- Testing
- Oxygen
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Northwell Health
Chronic Obstructive Pulmonary Disease
Correlation Between Handgrip Strength and Air Trapping in Patients with Stable Chronic Obstructive Pulmonary Disease
The goal of this observational study is to investigate the relationship between handgrip strength and air trapping in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT06220851
- Testing
- Handgrip strength
- Where
- Thailand
- Volunteers
- 72 people
- Sponsor
- Thammasat University
Pulmonary Disease, Chronic Obstructive
Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This multicenter study will be conducted to compare the effect of FF/UMEC/VI with FF/VI plus UMEC on lung function after 24 weeks of treatment.
- Trial name
- NCT02729051
- Testing
- FF/UMEC/VI, FF/VI, UMEC
- Where
- 127 sites in Argentina, Australia and 10 more
- Volunteers
- 1,055 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.